A randomized phase III trial for advanced pancreatic cancer comparing gemcitabine with gemcitabine plus capecitabine has again demonstrated that combination chemotherapy provides no significant outcome advantage for patients. A marked change in treatment paradigm is essential if therapeutic interventions are to move beyond the persistently dismal outcome results for the majority of pancreatic cancer patients, as exemplified by the past decade of clinical research.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Quantitation of deoxynucleoside triphosphates by click reactions
Scientific Reports Open Access 17 January 2020
-
CtBP—a targetable dependency for tumor-initiating cell activity and metastasis in pancreatic adenocarcinoma
Oncogenesis Open Access 04 October 2019
-
Cancer Cell Mitochondria Targeting by Pancratistatin Analogs is Dependent on Functional Complex II and III
Scientific Reports Open Access 21 February 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. et al. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).
Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2 7, 5513–5518 (2009).
Scheithauer, W. et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann. Oncol. 14, 97–104 (2003).
Herrmann, R. et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreas cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Group. J. Clin. Oncol. 25, 2212–2217 (2007).
Tabernero, J. & Macarulla, T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J. Clin. Oncol. 27, 5487–5491 (2009).
Philip, P. A. et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 27, 5660–5669 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors are Consultants and receive grant/research support from Roche.
Rights and permissions
About this article
Cite this article
Berlin, J., Benson III, A. Gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol 7, 135–137 (2010). https://doi.org/10.1038/nrclinonc.2010.16
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.16